Potential role of tryptophan catabolism in cancer-related cognitive impairment

被引:1
|
作者
Eroglu, Imdat [1 ]
Eroglu, Burcu Celik [1 ]
机构
[1] Hacettepe Univ, Dept Internal Med, Fac Med, Ankara, Turkey
关键词
Cancer; Cognitive; Impairment; Breast; Tryptophan; BREAST-CANCER; INDOLEAMINE 2,3-DIOXYGENASE; KYNURENINE PATHWAY; ADJUVANT CHEMOTHERAPY; HIPPOCAMPAL; INHIBITION; DYSFUNCTION; METABOLISM; INDUCTION; THERAPY;
D O I
10.1016/j.nut.2022.111765
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Oncology may be the most rapidly expanding field in medicine, with several innovative diagnostic and thera-peutic procedures appearing daily. Advances in oncology have improved the survival rate for patients with cancer and promoting quality of life is now one of the goals in the care of these patients. Patients face a vari-ety of disease-and treatment-related side effects, including anorexia, nausea, vomiting, recurring infections, and sleep difficulties. Cancer-related cognitive impairment (CRCI) is an overlooked clinical condition found in oncologic practice, particularly in patients with breast cancer. Although several potential mechanisms for CRCI have been hypothesized, to our knowledge, the exact mechanism is still unknown. Alterations in the tryptophan kynurenine pathway have been shown to impair cognitive skills in several mental illnesses. How-ever, its possible function in CRCI has yet to be investigated. The aim of this was to examine the possible interactions between tryptophan catabolism and CRCI.(c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Cancer-related cognitive impairment and patients' ability to work: a current perspective
    Duijts, Saskia F. A.
    van der Beek, Allard J.
    Boelhouwer, Ingrid G.
    Schagen, Sanne B.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2017, 11 (01) : 19 - 23
  • [22] Prevalence, mechanisms, and management of cancer-related cognitive impairment
    Janelsins, Michelle C.
    Kesler, Shelli R.
    Ahles, Tim A.
    Morrow, Gary R.
    INTERNATIONAL REVIEW OF PSYCHIATRY, 2014, 26 (01) : 102 - 113
  • [23] Cognitive behavioral therapy for cancer-related cognitive dysfunction
    Kucherer, Shelly
    Ferguson, Robert J.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2017, 11 (01) : 46 - 51
  • [24] Cancer-related cognitive impairment and its relation to PTSD
    Robins, H. Ian
    Johnson, Laddie
    LoConte, Noelle
    Brandt, Kimberly
    BREAST, 2017, 34 : 134 - 134
  • [25] A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment
    Horowitz, Todd S.
    Suls, Jerry
    Trevino, Melissa
    TRENDS IN NEUROSCIENCES, 2018, 41 (08) : 493 - 496
  • [26] Genetic risk factors for cancer-related cognitive impairment: a systematic review
    Buskbjerg, Cecilie D. R.
    Amidi, Ali
    Demontis, Ditte
    Nissen, Eva R.
    Zachariae, Robert
    ACTA ONCOLOGICA, 2019, 58 (05) : 537 - 547
  • [27] Coping with cancer-related cognitive dysfunction: a scoping review of the literature
    Sleight, Alix
    DISABILITY AND REHABILITATION, 2016, 38 (04) : 400 - 408
  • [28] Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment
    Lycke, Michelle
    Pottel, Lies
    Pottel, Hans
    Ketelaars, Lore
    Stellamans, Karin
    Van Eygen, Koen
    Vergauwe, Philippe
    Werbrouck, Patrick
    Goethals, Laurence
    Schofield, Patricia
    Boterberg, Tom
    Debruyne, Philip R.
    PSYCHO-ONCOLOGY, 2017, 26 (05) : 632 - 639
  • [29] Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors
    Eisenberg, Stacy A.
    Kurita, Keiko
    Taylor-Ford, Megan
    Agus, David B.
    Gross, Mitchell E.
    Meyerowitz, Beth E.
    PSYCHO-ONCOLOGY, 2015, 24 (02) : 228 - 235
  • [30] The Developmental Trajectory of Cancer-Related Cognitive Impairment in Breast Cancer Patients: A Systematic Review of Longitudinal Neuroimaging Studies
    Sousa, Helena
    Almeida, Susana
    Bessa, Joao
    Pereira, M. Graca
    NEUROPSYCHOLOGY REVIEW, 2020, 30 (03) : 287 - 309